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Incidence of Extended-Spectrum--Lactamase-Producing Escherichia
coli and Klebsiella pneumoniae Isolates That Test Susceptible to
Cephalosporins and Aztreonam by the Revised CLSI Breakpoints
Carla S. McWilliams,a* Susan Condon,b Rebecca M. Schwartz,c,d Christine C. Ginocchiob,d
North Shore-LIJ Health System, Division of Infectious Diseases, Department of Medicine, Manhasset, New York, USAa; North Shore-LIJ Health System Laboratories,
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The incidence of aztreonam and cephalosporin susceptibility, determined using the revised CLSI breakpoints, for extended-
spectrum--lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates was evaluated. Our analysis
showed that results for aztreonam and/or>1 cephalosporin were reported as susceptible or intermediate for 89.2% of ESBL-
producing E coli isolates (569/638 isolates) and 67.7% of ESBL-producing K. pneumoniae isolates (155/229 isolates).
Extended-spectrum--lactamase (ESBL)-producing Entero-bacteriaceae strains represent a challenging problem for health
care providers, particularly in acute-care and long-term-care fa-
cilities and more recently in community-acquired infections (1–
5). ESBL enzymes are capable of inactivating penicillins, aztreo-
nam, cephalosporins, and-lactamase inhibitors, which limits the
number of effective antibiotics for treatment (1, 2, 4, 5).
The presence of an ESBL is suspected in Escherichia coli and
Klebsiella pneumoniae infections when resistance to one or more
of the extended-spectrum cephalosporins (ESCs) (cefotaxime,
ceftazidime, ceftriaxone, or cefepime) is detected (1, 2, 4). Based
on pre-2010 guidelines from the Clinical and Laboratory Stan-
dards Institute (CLSI) (Wayne, PA), laboratories then confirmed
the presence of an ESBL using labor-intensive manual methods.
This supplemental testing often delayed ESBL identification by 24
to 48 h. Confirmatory testing for ESBLs has also been incorpo-
rated into automated susceptibility test systems. Since resistance
to some ESCs and aztreonam may not always be detected by in
vitro methods, strains were reported as resistant to all penicillins,
cephalosporins (excluding the cephamycins), and aztreonam
based on positive confirmatory test results, independent of the
initial susceptibility test results. These guidelines were followed to
prevent strains being reported inadvertently as being susceptible
to ESCs and aztreonam, leading to potentially inappropriate treat-
ment.
In 2010, the CLSI Antibiotic Subcommittee lowered the MIC
breakpoints and increased the disk diffusion size criteria for re-
porting of aztreonam, cefazolin, cefotaxime, ceftizoxime, ceftriax-
one, and ceftazidime results. Interpretive criteria for cefuroxime
and cefepime were not changed, because the committee deter-
mined that the available data did not support any changes in the
breakpoints for these two drugs (6). In 2014, the CLSI recom-
mended changing the MIC breakpoints for cefepime to2g/ml
for sensitive, 4 to 8g/ml for sensitive dose dependent (SDD), and
16 g/ml for resistant (7). The CLSI advises that treatment of
ESBL-producing strains can be predicted solely on the basis of
MIC values, regardless of the underlying resistance mechanisms.
More-stringent interpretive criteria would eliminate the need for
confirmatory testing for ESBL, and results could be reported as
tested. In theory, this would decrease the time needed to identify
ESBL-producing Enterobacteriaceae and the costs associated with
additional laboratory work.
There were significant concerns that the 2010 interpretive cri-
teria might not detect all resistance, based on studies that demon-
strated that MICs do not always predict clinical responses, inocu-
lum effects may decrease the potential to detect subpopulations
with different susceptibility profiles, different test methods can
yield different results, and MIC results are not always reproducible
and can vary by3 dilutions (8). Therefore, we evaluated the rates
of cephalosporin and aztreonam susceptibility that would be re-
ported when using the lower breakpoints for ESBL-producing E.
coli and ESBL-producing K. pneumoniae.
A total of 638 unique ESBL-producing E. coli and 229 unique
ESBL-producingK. pneumoniae clinical isolates collected between
October 2012 and December 2012 were selected. Isolate specimen
sources are listed in Tables 2 and 4. Microscan Gram-negative
MIC panel 61 (Siemens, Tarrytown, NY) was used to determine
antimicrobial susceptibility profiles. The panel contains confir-
matory wells for ESBL (cefotaxime and clavulanate at 0.25 and 4.0
g/ml or 2.0 and 4.0 g/ml, respectively). MIC values were inter-
preted as sensitive, intermediate, or resistant results based on 2010
CLSI breakpoints for aztreonam, cefotaxime, ceftazidime, and
ceftriaxone. Cefepime interpretations were evaluated using 2010
and 2014 guidelines. Descriptive analyses of the numbers and per-
centages of categorical interpretations incorrectly reported as sen-
sitive or intermediate were determined using SPSS version 21 sta-
tistical software.
Based on 2010 breakpoints, 89.2% of ESBL-producing E. coli
strains (569/638 strains) would have been reported as sensitive or
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intermediate for aztreonam (19.1%) and/or 1 cephalosporin,
i.e., ceftazidime (31.8%), cefepime (27.7%), cefuroxime (4.7%),
ceftriaxone (3.4%), or cefotaxime (2.2%) (Table 1). A total of 170
E. coli isolates (26.6%) were reported as sensitive or intermediate
for multiple (2 to 6) drugs. Categorical interpretations according
to specimen sources are listed in Table 2. Evaluation of ESBL-
producing K. pneumoniae isolates demonstrated that 67.7% (155/
229 isolates) would have been reported as sensitive or intermedi-
ate for aztreonam (7.0%) and/or one or more cephalosporins, i.e.,
cefepime (38.0%), ceftazidime (9.2%), cefuroxime (5.2%), cefo-
taxime (4.4%), or ceftriaxone (4.0%) (Table 3). Twenty-six iso-
lates (11.4%) were incorrectly reported as sensitive or intermedi-
ate for multiple (2 to 6) drugs. Categorical interpretations
according to specimen sources are listed in Table 4. The 2014
cefepime breakpoints increased the reporting of the resistant cat-
egory from 72.3% to 80.3% for ESBL-producing E. coli isolates
and from 62% to 70.7% for ESBL-producing K. pneumoniae iso-
lates.
Our data are similar to those of Kristo et al., who found that
6.4% of the ESBL-producing strains were susceptible to cefo-
taxime, 44.6% to ceftazidime, and 55.4% to cefepime; as many as
71.8% were susceptible to at least one ESC (9). Among the E. coli
isolates examined, 8.0%, 58.0%, and 52.7% were called suscepti-
ble to cefotaxime, ceftazidime, and cefepime, respectively; among
the K. pneumoniae isolates, 2.3%, 7.0%, and 58.1% were called
susceptible to the aforementioned ESCs. Wang et al. found that,
with the new breakpoints, 41.8 to 45.6% of ESBL-producingE. coli
strains appeared to be susceptible to ceftazidime and cefepime and
20.1% of ESBL-producing K. pneumoniae strains were susceptible
to cefepime (10).
These data show that, by eliminating confirmatory testing for
ESBL, a laboratory would report a significant number of ESBL-
producing E. coli and K. pneumoniae strains as susceptible or in-
termediate for aztreonam and one or more ESCs, including ap-
proximately 20% of the isolates for cefepime. Pharmacokinetic
(PK)-pharmacodynamic (PD) models based primarily on Monte
Carlo simulations have demonstrated that the use of higher doses
of cefepime in the presence of an ESBL-producing strain may
achieve time above the MIC (free fraction of the dosing interval)
of at least 50% (11, 12). Published data are limited by retrospective
study designs, smaller sample sizes, and lack of prospective ran-
domization (13). No head-to-head trials of cefepime versus a car-
bapenem for treatment of ESBL-producing E. coli or K. pneu-
moniae isolates have been published to date.
The 2010 and 2014 CLSI breakpoints were instituted to reflect
more accurately the clinical efficacy of these drugs with contem-
porary isolates, recommended antibiotic dosage regimens, and a
better understanding of PK-PD data. Not all types of ESBLs confer
resistance to aztreonam and/or ESCs, which could be therapeuti-
cally effective. However, susceptibility test results can be inaccu-
rate due to the type of ESBL present, the resistance mechanism,
inoculum effects, or testing variability. Inoculum effects in the
TABLE 1 Susceptibility profiles of 638 ESBL-producing E. coli isolates,
interpreted using 2010 and 2014 CLSI breakpoints
Drug
No. (%) with CLSI interpretation of:
Sensitive Intermediate Resistant
Aztreonam 69 (10.8) 53 (8.3) 516 (80.9)
Cefotaxime 0 (0) 14 (2.2) 624 (97.8)
Ceftazidime 141 (22.1) 62 (9.7) 435 (68.2)
Ceftriaxone 18 (2.8) 4 (0.6) 616 (96.6)
Cefuroxime 23 (3.6) 7 (1.1) 608 (95.3)
Cefepime
2010 breakpoints 126 (19.7) 51 (8.0) 461 (72.3)
2014 breakpoints 126 (19.7)a 512 (80.3)
a Sensitive or sensitive dose dependent.
TABLE 2 Susceptibility profiles of ESBL-producing E. coli isolates










Blood 34 2 (5.9) 9 (26.5) 23 (67.6)
Bronchial secretion or
sputum
13 2 (15.4) 2 (15.4) 9 (69.2)
Surgical or tissue specimen 15 3 (20.0) 4 (26.7) 8 (53.3)
Urine 537 86 (16.0) 140 (26.1) 311 (57.9)
Unknown 30 2 (6.7) 12 (40.0) 16 (53.3)
Total 638 95 (14.9) 170 (26.7) 373 (58.5)
a Throat, skin, rectal, and genital swabs (n 9) are not listed.
b The drugs evaluated were aztreonam, cefotaxime, ceftazidime, ceftriaxone,
cefuroxime, and cefepime.
TABLE 3 Susceptibility profiles of ESBL-producing K. pneumoniae
isolates, interpreted using 2010 and 2014 CLSI breakpoints
Drug
No. (%) with CLSI interpretation of:
Sensitive Intermediate Resistant
Aztreonam 11 (4.8) 5 (2.2) 213 (93.0)
Cefotaxime 0 (0) 10 (4.4) 219 (95.6)
Ceftazidime 13 (5.7) 8 (3.5) 208 (90.8)
Ceftriaxone 7 (3.1) 2 (0.9) 220 (96.1)
Cefuroxime 8 (3.5) 4 (1.7) 217 (94.8)
Cefepime
2010 breakpoints 67 (29.3) 20 (8.7) 142 (62.0)
2014 breakpoints 67 (29.3)a 162 (70.7)
a Sensitive or sensitive dose dependent.
TABLE 4 Susceptibility profiles of ESBL-producing K. pneumoniae











Blood 26 7 (26.9) 3 (11.5) 16 (61.5)
Bronchial secretion or
sputum
17 6 (35.3) 2 (11.8) 9 (52.9)
Surgical or tissue specimen 7 0 (0) 0 (0) 7 (100)
Urine 166 52 (31.3) 19 (11.4) 95 (57.2)
Unknown 13 2 (15.4) 2 (15.4) 9 (69.2)
Total 229 67 (29.3) 26 (11.4) 136 (59.4)
a The drugs evaluated were aztreonam, cefotaxime, ceftazidime, ceftriaxone,
cefuroxime, and cefepime.
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host are complex and involve multiple factors (e.g., patient
weight, drug metabolism, renal function, and site of infection)
that can be only partially accounted for in laboratory models.
Again, most available data are from in vitro studies, and infectious
disease physicians are wary of how such data apply in vivo, partic-
ularly for patients with more-serious infections such as bactere-
mia (14–18). Therefore, the standard of care for managing infec-
tions due to ESBL-producing organisms is treatment with a
carbapenem. Clinical outcome studies must sufficiently assess the
true clinical responses and determine the appropriate use of az-
treonam and ESCs for the treatment of infections due to ESBL-
producing Enterobacteriaceae strains. Physicians, pharmacists,
and microbiologists should be aware of the frequency of reports of
susceptible/intermediate results for aztreonam and/or ESCs for
ESBL-producing Enterobacteriaceae strains when the 2010/2014
interpretive guidelines are used. This information should facilitate
the development of institutional policies for both treatment and
the reporting of susceptibilities for aztreonam and ESCs.
The major limitation of the study was that it was retrospective
and therefore no genetic analysis was performed to determine
specific resistance mechanisms. Nonetheless, based on these data,
our institution determined that, until more clinical outcome data
are available, susceptibility reporting using a combination of the
lowered breakpoints and confirmatory ESBL testing, with adjust-
ment of reporting for aztreonam and ESCs, will be continued.
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